The role of the complement system in age-related macular degeneration., PMID:24622760
Complement inhibition in cynomolgus monkeys by anti-factor d antigen-binding fragment for the treatment of an advanced form of dry age-related macular degeneration., PMID:25232192
Outer retinal tubulation as a predictor of the enlargement amount of geographic atrophy in age-related macular degeneration., PMID:25315664
Antibody therapies and their challenges in the treatment of age-related macular degeneration., PMID:25725263
Potential role of lampalizumab for treatment of geographic atrophy., PMID:26089637
Potential role of lampalizumab for treatment of geographic atrophy [Retraction]., PMID:26170604
A mechanistic pharmacokinetic/pharmacodynamic model of factor D inhibition in cynomolgus monkeys by lampalizumab for the treatment of geographic atrophy., PMID:26359312
Emixustat and Lampalizumab: Potential Therapeutic Options for Geographic Atrophy., PMID:26501510
Population Pharmacokinetics and Pharmacodynamics of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy., PMID:26535160
Corticosteroids and Anti-Complement Therapy in Retinal Diseases., PMID:27815789
Functional Reading Independence (FRI) Index: A New Patient-Reported Outcome Measure for Patients With Geographic Atrophy., PMID:27893095
Antibodies to watch in 2017., PMID:27960628
Recent advances in the management and understanding of macular degeneration., PMID:28491291
Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration., PMID:28637922
Age-related macular degeneration foils drugmakers., PMID:29121027
Nonclinical Safety Assessment of Anti-Factor D: Key Strategies and Challenges for the Nonclinical Development of Intravitreal Biologics., PMID:29148965
Latest Developments in the Management of AMD., PMID:29204992
Antibodies to watch in 2018., PMID:29300693
[AMD and complement pathway in 2017]., PMID:29337453
Reliability and Construct Validity of the NEI VFQ-25 in a Subset of Patients With Geographic Atrophy From the Phase 2 Mahalo Study., PMID:29530781
Alterations in Extracellular Matrix/Bruch's Membrane Can Cause the Activation of the Alternative Complement Pathway via Tick-Over., PMID:29721924
Therapeutic effects of various therapeutic strategies on non-exudative age-related macular degeneration: A PRISMA-compliant network meta-analysis of randomized controlled trials., PMID:29794727
Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials., PMID:29801123
Maximum Reading Speed in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration., PMID:30383205
In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches., PMID:30444371
Complement inhibition as a therapeutic strategy in retinal disorders., PMID:30686077
Pharmacological Advances in the Treatment of Age-related Macular Degeneration., PMID:31362645
Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis., PMID:31910414
Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials., PMID:32081489
Visual Function Decline Resulting from Geographic Atrophy: Results from the Chroma and Spectri Phase 3 Trials., PMID:32199866
Novel approach to antiangiogenic factors in age-related macular degeneration therapy., PMID:35600160
Deep Learning to Predict Geographic Atrophy Area and Growth Rate from Multimodal Imaging., PMID:36038116
Towards a Therapy for Geographic Atrophy: A Patient's Experience., PMID:36756537
Alternative Complement Pathway Inhibition by Lampalizumab: Analysis of Data From Chroma and Spectri Phase III Clinical Trials., PMID:37228694
The Role of the Complement Pathway in Clinical Progression of Geographic Atrophy: Analysis of the Phase III Chroma and Spectri Trials., PMID:37304044
Complement inhibitors for age-related macular degeneration., PMID:37314061
Macular Sensitivity Endpoints in Geographic Atrophy: Exploratory Analysis of Chroma and Spectri Clinical Trials., PMID:37869030
Investigational drugs inhibiting complement for the treatment of geographic atrophy., PMID:37902056
Drug Approval for the Treatment of Geographic Atrophy: How We Got Here and Where We Need to Go., PMID:38387826
Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy: A 12-Month Post Hoc Analysis of the GATHER1 and GATHER2 Trials., PMID:38719191
Intraocular Pressure Outcomes After Lampalizumab Injections in Patients With Geographic Atrophy., PMID:38900484
Quantitative comparison of automated OCT and conventional FAF-based geographic atrophy measurements in the phase 3 OAKS/DERBY trials., PMID:39227682
Complement Inhibitors for Geographic Atrophy in Age-Related Macular Degeneration-A Systematic Review., PMID:39338244
Visual Loss in Geographic Atrophy: Learnings from the Lampalizumab Trials., PMID:39581330
Deep Learning to Predict the Future Growth of Geographic Atrophy from Fundus Autofluorescence., PMID:39758130
Deep Learning Approaches to Predict Geographic Atrophy Progression Using Three-Dimensional OCT Imaging., PMID:39913124
Reading Performance in Geographic Atrophy: Comparison of Different Reading Speed Measures for Capturing Longitudinal Changes., PMID:40124312
Alterations in Extracellular Matrix/Bruch's Membrane Can Cause the Activation of the Alternative Complement Pathway via Tick-Over, PMID: 29721924
Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials, PMID: 32081489
Outer retinal tubulation as a predictor of the enlargement amount of geographic atrophy in age-related macular degeneration, PMID: 25315664
Reliability and Construct Validity of the NEI VFQ-25 in a Subset of Patients With Geographic Atrophy From the Phase 2 Mahalo Study, PMID: 29530781
Complement inhibition in cynomolgus monkeys by anti-factor d antigen-binding fragment for the treatment of an advanced form of dry age-related macular degeneration, PMID: 25232192
Nonclinical Safety Assessment of Anti-Factor D: Key Strategies and Challenges for the Nonclinical Development of Intravitreal Biologics, PMID: 29148965
Functional Reading Independence (FRI) Index: A New Patient-Reported Outcome Measure for Patients With Geographic Atrophy, PMID: 27893095
Maximum Reading Speed in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration, PMID: 30383205
Age-related macular degeneration foils drugmakers, PMID: 29121027
Therapeutic effects of various therapeutic strategies on non-exudative age-related macular degeneration: A PRISMA-compliant network meta-analysis of randomized controlled trials, PMID: 29794727
Corticosteroids and Anti-Complement Therapy in Retinal Diseases, PMID: 27815789
Antibody therapies and their challenges in the treatment of age-related macular degeneration, PMID: 25725263
The role of the complement system in age-related macular degeneration, PMID: 24622760
Recent advances in the management and understanding of macular degeneration, PMID: 28491291
Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration, PMID: 28637922
Latest Developments in the Management of AMD, PMID: 29204992
[AMD and complement pathway in 2017], PMID: 29337453
Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis, PMID: 31910414
In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches, PMID: 30444371
Antibodies to watch in 2018, PMID: 29300693
Antibodies to watch in 2017, PMID: 27960628
Visual Function Decline Resulting from Geographic Atrophy: Results from the Chroma and Spectri Phase 3 Trials, PMID: 32199866
A mechanistic pharmacokinetic/pharmacodynamic model of factor D inhibition in cynomolgus monkeys by lampalizumab for the treatment of geographic atrophy, PMID: 26359312
Population Pharmacokinetics and Pharmacodynamics of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy, PMID: 26535160
Pharmacological Advances in the Treatment of Age-related Macular Degeneration, PMID: 31362645
Complement inhibition as a therapeutic strategy in retinal disorders, PMID: 30686077
Emixustat and Lampalizumab: Potential Therapeutic Options for Geographic Atrophy, PMID: 26501510
Potential role of lampalizumab for treatment of geographic atrophy, PMID: 26089637
Potential role of lampalizumab for treatment of geographic atrophy [Retraction], PMID: 26170604
Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials, PMID: 29801123
For research use only. Not for human or drug use.
